Vaccines for pandemic influenza
Author(s)
Bibliographic Information
Vaccines for pandemic influenza
(Current topics in microbiology and immunology, v. 333)
Springer, c2009
Available at 17 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Description and Table of Contents
Description
Recent years have seen unprecedented outbreaks of avian influenza A viruses. In particular, highly pathogenic H5N1 viruses have not only resulted in widespread outbreaks in domestic poultry, but have been transmitted to humans, resulting in numerous fatalities. The rapid expansion in their geographic distribution and the possibility that these viruses could acquire the ability to spread from person to person raises the risk that such a virus could cause a global pandemic with high morbidity and mortality. An effective influenza vaccine represents the best approach to prevent and control such an emerging pandemic. However, current influenza vaccines are directed at existing seasonal influenza viruses, which have little or no antigenic relationship to the highly pathogenic H5N1 strains. Concerns about pandemic preparedness have greatly stimulated research activities to develop eff- tive vaccines for pandemic influenza viruses, and to overcome the limitations inh- ent in current approaches to vaccine production and distribution. These limitations include the use of embryonated chicken eggs as the substrate for vaccine prod- tion, which is time-consuming and could involve potential biohazards in growth of new virus strains. Other limitations include the requirement that the current inac- vated influenza vaccines be administered using needles and syringes, requiring trained personnel, which could be a bottleneck when attempting to vaccinate large populations in mass campaigns. In addition, the current inactivated vaccines that are delivered by injection elicit limited protective immunity in the upper respiratory tract where the infection process is initiated.
Table of Contents
Preface.- Pandemic influenza as a current threat.- Designing vaccines for pandemic influenza.- Current vaccines for seasonal influenza.- Generation and characterization of candidate vaccine viruses for pre-pandemic influenza vaccines.- Recombinant proteins produced in insect cells.- Adjuvants for pandemic influenza vaccines.- Live attenuated vaccines for pandemic influenza.- Influenza vaccines for avian species.- Development and application of avian influenza vaccines in China.- Attenuated influenza virus vaccines with modified NS1 proteins.- DNA Vaccines against Influenza viruses.- Influenza neuraminidase as a vaccine antigen.- Recombinant vectors as influenza vaccines.- Universal Pandemic Influenza Vaccines.- Influenza virus-like particles as pandemic vaccines.- Antigenic cross-reactivity among H5N1 viruses.- Transcutaneous immunization with influenza vaccines.- Self-administered microneedle patches for pandemic influenza.- Animal models for evaluation of influenza vaccines.- Immunosenescence and influenza vaccine efficacy.- Summary of recent clinical trials.- Considerations for licensure of pandemic and pre-pandemic indications in the U.S..- Strategies for Broad Global Access to Pandemic Influenza Vaccines.- Prioritization of Pandemic Influenza Vaccine: Rationale and Strategy for Decision-Making.- Subject index.
by "Nielsen BookData"